Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using...

Area of Science:

• Genomics
• Oncology
• Molecular Diagnostics

Background:

• Genomic abnormalities in B-cell chronic lymphocytic leukemia (CLL) are crucial for prognosis.
• Current diagnostic methods like FISH and MLPA are targeted and may miss certain alterations.
• Microarray-based genomic profiling offers high-resolution, genome-wide analysis.

Purpose of the Study:

• To compare two new microarray platforms (Affymetrix CytoScan HD and Illumina HumanOmniExpress) with FISH and MLPA.
• To evaluate the potential of microarray platforms to replace current diagnostic tests for CLL.
• To assess the diagnostic accuracy and detection limits of the microarray platforms.

Main Methods:

• Genomic profiling using Affymetrix CytoScan HD and Illumina HumanOmniExpress arrays.
• Fluorescence in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA) were performed for comparison.
• Analysis of 28 CLL patients, including 9 evaluated on both microarray platforms and 7 with low-percentage abnormalities.

Main Results:

• Both microarray platforms identified identical genomic aberrations when compared.
• Microarray platforms detected copy number abnormalities present in as few as 16% of cells.
• Microarray profiling identified additional abnormalities missed by FISH/MLPA, including focal TP53 loss and copy-neutral loss of heterozygosity on chromosome 17p.

Conclusions:

• Microarray platforms offer comparable results to FISH and MLPA, with a slightly lower detection limit but still effective down to 16% of cells.
• These platforms can identify novel, potentially prognostic genomic alterations not detectable by current methods.
• Further clinical trials are needed to confirm the prognostic significance of these newly identified genomic alterations in CLL.